Proactively evaluate Xencor Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
|Event Date||Event Type||Company Name||Ticker Symbol||Drug Name||Therapy Area||Indication||Source Type|
|31 Dec 2020||GDCTXXXX||Lorem||Lorem||Lorem||XXXX||Planned||Lorem|
|30 Jun 2020||Phase I Trial Results||ICON Plc; Xencor Inc||ICLR; XNCR||tidutamab||Oncology||Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Tumor; Lung Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Neuroendocrine Tumors; Pancreatic Cancer; Solid Tumor||Company Press Release|
|31 Dec 2019||IND Filing (US)||Xencor Inc||XNCR||XmAb-306||Oncology||-||Company Press Release|
|31 Dec 2019||Phase I Trial Results||ICON Plc; Xencor Inc||ICLR; XNCR||plamotamab||Hematological Disorders; Oncology||B-Cell Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma; Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma); Follicular Lymphoma; Hematological Tumor; Lymphoma; Mantle Cell Lymphoma; Nodal Marginal Zone B-Cell Lymphoma; Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed Chronic Lymphocytic Leukemia (CLL); Splenic Marginal Zone B-Cell Lymphoma; Unspecified B-Cell Lymphomas; Unspecified Hematological Disorders; Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)||Company Presentation|
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer